Grants

awarded

The METAvivor Research Program was established in 2009 with the specific goal of funding stage IV metastatic breast cancer research to one day, end death from metastatic breast cancer (MBC). The following list includes current and past grant recipients along with their progress reports.

Robert Schneider, PhD

New York University School of Medicine

Presented by Abbey Rapoport

Inhibition of Regulatory T cell (Treg) selective mRNA translation for the treatment of metastatic breast cancer metastasis

Axel Schönthal, PhD

University of Southern California

Presented in memory of Kerry O’Riordan McAdam and In Honor of Jacqueline Beck

Controlled Opening of the Blood-Brain Barrier to Enable Effective Therapeutic Access to Breast Cancer Brain Metastases

AXEL SCHÖNTHAL, PhD

University of Southern California

Controlled Opening of the Blood-Brain Barrier to Achieve Therapeutic Access of Trastuzumab in HER2-Positive Brain Metastases

KATHRYN SCHWERTFEGER, PhD

University of Minnesota

Development of Immune-based Strategies to Enhance Therapeutic Targeting of Metastatic Breast Cancer

TIFFANY SEAGROVES, PhD

University of Tennesee Health Science Center

Targeting Creatine Kinases to Inhibit Metastatic Breast Cancer

Andrew D. Seidman, MD

Memorial Sloan Kettering Cancer Center

Presented by Cycle4Helen in honor of Helen O’Leary

Untangling the role of the brain metastasis microenvironment in HER2 positive breast cancer brain metastases to inform rational systemic treatment strategies

GEORGE SGOUROS, PhD

Johns Hopkins University, School of Medicine

A Pre-Clinical Model of anti-HER2/neu-Antibody Reactive Breast Cancer Metastases

Ayesha Shajahan-Haq, PhD

Georgetown University

Presented by METAvivor’s community of followers on social media in honor of all of those touched by metastatic breast cancer

Application of a novel ruthenium-based anticancer therapy in ER+ metastatic breast cancer

Ghada Sharif, PhD

Lombardi Comprehensive Cancer Center

Presented by Color Street Foundation

Targeting Occult Cancer Cell Subpopulations Driving Metastases Growth

Dipali Sharma, MS, PhD

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkin

Presented by Color Street Foundation

Racial Disparity in metastatic triple-negative breast cancer in African American women: Unraveling actionable molecular determinants

PATRICIA SHEEAN, PhD, RDN

Loyola University Chicago

Is lean soft tissue (i.e., skeletal muscle) a potentially modifiable biomarker predictive of prognosis, treatment tolerance and

HAIFA SHEN, PhD, MD

Houston Methodist Research Institute

Harnessing Vascular and Cellular Depots of Nanotherapeutics for the Treatment of Metastatic Breast Cancer